These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31084442)

  • 1. An economic evaluation attached to a single-centre, parallel group, unmasked, randomized controlled trial of a 3-day intensive social cognitive treatment (can do treatment) in patients with relapsing remitting multiple sclerosis and low disability.
    van Mastrigt GA; Evers SM; Heerings M; Visser LH; Ruimschotel RP; Hussaarts A; Duyverman L; Valkenburg-Vissers J; Cornelissen J; Bos M; van Droffelaar M; Jongen PJ
    J Med Econ; 2019 Oct; 22(10):967-980. PubMed ID: 31084442
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of an intensive 3-day social cognitive treatment (can do treatment) on control self-efficacy in patients with relapsing remitting multiple sclerosis and low disability: A single-centre randomized controlled trial.
    Jongen PJ; van Mastrigt GA; Heerings M; Visser LH; Ruimschotel RP; Hussaarts A; Duyverman L; Valkenburg-Vissers J; Cornelissen J; Bos M; van Droffelaar M; Donders R
    PLoS One; 2019; 14(10):e0223482. PubMed ID: 31600271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocol.
    Jongen PJ; Heerings M; Ruimschotel R; Hussaarts A; Evers S; Duyverman L; Valkenburg-Vissers J; Cornelissen J; Bos M; van Droffelaar M; Lemmens WA; Donders R; van der Zande A; Visser LH
    BMC Neurol; 2016 May; 16():81. PubMed ID: 27234001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis.
    Thomas S; Thomas PW; Kersten P; Jones R; Green C; Nock A; Slingsby V; Smith AD; Baker R; Galvin KT; Hillier C
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1092-9. PubMed ID: 23695501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study.
    Jongen PJ; Ruimschotel R; Heerings M; Hussaarts A; Duyverman L; van der Zande A; Valkenburg-Vissers J; Wolper H; van Droffelaar M; Lemmens W; Donders R; Visser LH
    Health Qual Life Outcomes; 2014 Mar; 12():40. PubMed ID: 24646061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of a pragmatic exercise intervention (EXIMS) for people with multiple sclerosis: economic evaluation of a randomised controlled trial.
    Tosh J; Dixon S; Carter A; Daley A; Petty J; Roalfe A; Sharrack B; Saxton JM
    Mult Scler; 2014 Jul; 20(8):1123-30. PubMed ID: 24421304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model.
    Kremer IEH; Hiligsmann M; Carlson J; Zimmermann M; Jongen PJ; Evers SMAA; Petersohn S; Pouwels XGLV; Bansback N
    Med Decis Making; 2020 Nov; 40(8):1003-1019. PubMed ID: 33174513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of perioperative enteral nutrition in patients undergoing colorectal surgery (SANICS II study).
    Pattamatta M; Evers SMAA; Smeets BJJ; Peters EG; Luyer MDP; Hiligsmann M
    J Med Econ; 2019 Mar; 22(3):238-244. PubMed ID: 30523724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Su W; Kansal A; Vicente C; Deniz B; Sarda S
    J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    Chevalier J; Chamoux C; Hammès F; Chicoye A
    PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial.
    Luciano JV; D'Amico F; Cerdà-Lafont M; Peñarrubia-María MT; Knapp M; Cuesta-Vargas AI; Serrano-Blanco A; García-Campayo J
    Arthritis Res Ther; 2014 Oct; 16(5):451. PubMed ID: 25270426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the disutility of relapse in relapsing-remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models.
    Ahmad H; Campbell JA; van der Mei I; Taylor BV; Xia Q; Zhao T; Palmer AJ
    Qual Life Res; 2023 Dec; 32(12):3373-3387. PubMed ID: 37522942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A trial-based economic evaluation of the Restore4Stroke self-management intervention compared to an education-based intervention for stroke patients and their partners.
    van Mastrigt GAPG; van Eeden M; van Heugten CM; Tielemans N; Schepers VPM; Evers SMAA
    BMC Health Serv Res; 2020 Apr; 20(1):294. PubMed ID: 32268896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
    Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R
    J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.